Cambridge Biomedical Campus - Virtual Tour Webinar
Digital, 24 Nov 2020
As a part of the new online webinar series by Cambridge Biomedical Campus ‘CBC on Virtual Tour’, Billy Boyle, Co-Founder and CEO of Owlstone Medical will be presenting 'Breath Biopsy–a New Paradigm for Early Detection of Cancer & Other Disease' on Tuesday 24th November at 19:00 – 20:00 GMT.
Register through this link to attend the event. All registered participants will be sent the Zoom link in their order confirmation.
More about this event:
It is a sobering statistic that one in two of us will get cancer in our lifetimes and cancer is the second leading cause of death globally. Early detection is our greatest opportunity, with estimates that if detected early, approximately half of lung cancer patients and three-quarters percent of colon cancer patients can be cured with treatments that exist today compared with only 5% and 10% respectively today.
Breath Biopsy has the potential to directly transform this dynamic by detecting volatile organic compounds produced or modified by metabolic processes within the body – changes in which can be characteristic of specific disease.
Billy Boyle is an engineering graduate from Cambridge University. He is one of the original co-founders of Owlstone Inc, spun out of Cambridge in 2004, which has raised $28 million in investment and won >$25 million in defence contracts. He initially worked with silicon foundries in the design and fabrication of the core microchip technology and is co-inventor on 19 patents. He then assumed a commercial role with P&L responsibility for the Scientific Instruments and Industrial business units; responsible for sales of FAIMS products and contracts with >150 clients globally, including Agilent, Thermo, Roche Diagnostics, Samsung, GSK, 4D Pharma, Mayo Clinic and the NHS.
Billy started to focus on the medical applications of FAIMS technology after his wife, Kate, was diagnosed and later died of colon cancer as a result of a late diagnosis. He worked closely with clinical partners who integrated FAIMS technology across a broad spectrum of clinical trials in cancer, inflammatory disease & infectious disease.
If you would like to talk to us about this event or anything else, please get in touch.
For press information please contact:
Sarah Jeffery, Zyme Communications
+44 (0)7771 730919
Learn more about breath biomarkers for disease in our free ebook: Breath Biopsy: The Complete Guide.